Abstract
The use of a combination of cytotoxic medications and hormone therapy/ gene therapy has been widely acknowledged as an established approach to treating metastatic prostate cancer. Nevertheless, the effectiveness of this approach is limited by the inadequate ability of the chemotherapy to reach tumor sites, leading to a higher occurrence of collateral damage and multidrug resistance (MDR). The use of nanovectorization techniques has developed into a successful method for achieving excellent therapeutic results. This technology has the potential to increase the targeted and less hazardous targeting mechanisms for anticancer action, as well as provide diagnostic imaging using theragnostic. While research on nanomedicine is prevalent in several cancer types, there has been less emphasis on its use specifcally in prostate cancer. This study offers a comprehensive understanding of the fundamental concepts behind nanotherapeutics and nanotheranostics, as well as their potential clinical implications in the treatment of prostate cancer. This study focuses on the clinical and preclinical data on the use of nanovectors in prostate cancer therapy techniques. Specifcally, we examine the possibilities and prospects of using homing nanovectorization in these tactics.
Original language | English |
---|---|
Title of host publication | Prostate Cancer |
Subtitle of host publication | Molecular Events and Therapeutic Modalities |
Publisher | Springer Nature |
Pages | 273-291 |
Number of pages | 19 |
ISBN (Electronic) | 9789819746125 |
ISBN (Print) | 9789819746118 |
DOIs | |
Publication status | Published - 26 Nov 2024 |
Keywords
- Liposomal nanoparticles
- Multidrug resistance (MDR)
- Nanotheranostics
- Non-AR therapeutic targets
- Permeability and retention (EPR) effect
ASJC Scopus subject areas
- General Medicine
- General Biochemistry,Genetics and Molecular Biology